Overview The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects Status: Completed Trial end date: 2019-02-25 Target enrollment: Participant gender: Summary The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects Phase: Phase 1 Details Lead Sponsor: Sunshine Lake Pharma Co., Ltd.